Editor's Note:This Week's Bullish Stocks in Hong Kong and the USThis section closely follows market trends every week, reviews the weekly performance of the Hong Kong and US stock markets, and helps mooers sort out the hot sectors, strong individual stocks, and major news of the week, looking for investment themes with profit potential.
This week, US stocks were severely impacted by the Federal Reserve's "hawkish interest rate cut" stance, with expectations for rate cuts next year reduced to two times. All three major indices fell back, with the Dow Jones Industrial Average marking a record for consecutive declines over half a century. As of Thursday's close, the Dow Jones Industrial Average had dropped a total of 3.39%, closing at 42,342.24 points; during the same period, the S&P 500 Index decreased by 3.04%, closing at 5,867.08 points; the Nasdaq Index fell 2.78%, closing at 19,372.77 points.
Nevertheless, there were still US companies with strong fundamentals that rose against the market trend. These companies have a total market capitalization of over 20 billion USD and an average daily trading volume exceeding 10 million USD.
In terms of specific stocks,$Teva Pharmaceutical Industries (TEVA.US)$the stock with the largest increase this week has risen by 29.15%.$Sanofi (SNY.US)$ The publication of the trial for treating intestinal diseases has reached its primary endpoint, and the stock price has hit a new high since early 2019.
Israeli pharmaceutical companies Teva Pharmaceutical Industries and Sanofi announced that their jointly developed treatment for inflammatory bowel disease, duvakitug, has achieved its primary endpoint in the latest trial. The two companies stated that patients with ulcerative colitis receiving duvakitug treatment had a higher clinical remission rate compared to the placebo group. A group of patients with Crohn's disease receiving duvakitug treatment achieved a higher remission rate than those receiving placebo treatment. Boosted by this news, Teva's stock soared over 26% on Tuesday, reaching its highest point since early 2019.
The American version of 'HAIDILAO' exceeded performance expectations! The steak restaurant LongHorn made outstanding contributions to performance.$Darden Restaurants (DRI.US)$ After the performance release, stock prices surged nearly 15%.
Darden Restaurants, which owns 10 dining brands, announced its first-quarter results for fiscal year 2025 on Thursday. The company's revenue was $2.8 billion, exceeding the expected $2.86 billion, and after the performance announcement, the stock price surged nearly 15%. Its main brand, steak restaurant LongHorn Steakhouse, continues to perform well, contributing to the overall positive results. Darden reaffirmed its full-year guidance, expecting mid to high single-digit earnings growth. The company plans to complete its acquisition of Chuy's before mid-October and start a pilot cooperation with Uber for takeout services in the second quarter.
Dow Jones Industrial Average component stocks. $Boeing (BA.US)$ This week, it rose against the market by 4.36%, receiving a large Order for 737 MAX aircraft, and resumed production at the beginning of this month.
On Thursday, Turkey's leading low-cost Airlines Pegasus announced a large Order for Boeing 737 MAX aircraft. This Trade includes a firm Order for 100 units of the 737 MAX 10 model, along with an option for an additional 100 aircraft. This Order size exceeds Pegasus's existing fleet, potentially reflecting the market's increasing confidence in the 737 MAX, which was previously grounded due to safety issues.
Sources familiar with Boeing's plans revealed that Boeing aims to achieve a monthly production of 38 737 MAX airplanes by May next year. The company confirmed last week that it has restarted the production of the 737 MAX at the beginning of this month.
On the other hand, the following stocks performed weakly this week:
Editor/Rocky